A Proteomic Study on the Personalized Protein Corona of Liposomes. Relevance for Early Diagnosis of Pancreatic DUCTAL Adenocarcinoma and Biomarker Detection

Journal of Nanotheranostics

Damiano Caputo¹  Alessandro Coppola¹  Vincenzo La Vaccara¹  Luca Digiacomo²  Francesca Giulimondi²  Giulio Caracciolo²  Daniela Pozzi² 

[1] General Surgery Unit, University Campus Bio-Medico di Roma, 00128 Rome, Italy;Nanodelivery Lab, Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy;

关键词: pancreatic cancer;    early detection;    cancer biomarkers;    biomolecular corona;   

DOI  :  10.3390/jnt2020006

来源: DOAJ

【 摘 要 】

Due to late diagnosis, high incidence of metastasis, and poor survival rate, pancreatic cancer is one of the most leading cause of cancer-related death. Although manifold recent efforts have been done to achieve an early diagnosis of pancreatic cancer, CA-19.9 is currently the unique biomarker that is adopted for the detection, despite its limits in terms of sensitivity and specificity. To identify potential protein biomarkers for pancreatic ductal adenocarcinoma (PDAC), we used three model liposomes as nanoplatforms that accumulate proteins from human plasma and studied the composition of this biomolecular layer, which is known as protein corona. Indeed, plasma proteins adsorb on nanoparticle surface according to their abundance and affinity to the employed nanomaterial, thus even small differences between healthy and PDAC protein expression levels can be, in principle, detected. By mass spectrometry experiments, we quantified such differences and identified possible biomarkers for PDAC. Some of them are already known to exhibit different expressions in PDAC proteomes, whereas the role of other relevant proteins is still not clear. Therefore, we predict that the employment of nanomaterials and their protein corona may represent a useful tool to amplify the detection sensitivity of cancer biomarkers, which may be used for the early diagnosis of PDAC, with clinical implication for the subsequent therapy in the context of personalized medicine.

【 授权许可】

Unknown